Proud to see INTRAGO-II published in The Lancet Oncology. This international Phase III trial advances our understanding of intraoperative radiotherapy in glioblastoma. Grateful to the investigators, collaborators, and patients who made this work possible.
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial - The Lancet Oncology https://t.co/Z7EvyoKHyQ
More exciting information about single dose intraoperative radiation therapy. Register for this year’s meeting at TARGITCollaborative site. San Diego, February 2-3. Hands on Laboratory! https://t.co/TsKiezeg7x
Frontiers | Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer—better for patients, better for healthcare systems https://t.co/o80nv20T0N
Frontiers | Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer—better for patients, better for healthcare systems https://t.co/o80nv20T0N
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer https://t.co/qObDsCae50